Sudeep Pharma Limited has intimated that its officials will participate in upcoming investor conferences scheduled for May 28 and June 8, 2026. The meetings are being held pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investor Conference Schedule

The company management will engage in one-on-one and group meetings with analysts and institutional investors. The discussions will be based solely on publicly available information, and no unpublished price sensitive information (UPSI) will be shared.

Conference Details

The first event is the 360 ONE Capital (B&K) 16th Annual Investor Conference, titled TRINITY INDIA 2026, set to take place on May 28. Following this, the company will attend the ICICI Securities India Investor Conference, themed "India Rising: The Next Chapter," on June 8. Both events will be conducted physically at the Grand Hyatt in Mumbai.

The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company. Dimple Mehta, Company Secretary & Compliance Officer, signed the intimation on May 23, 2026.

Sudeep pharma Limited has filed its quarterly compliance certificate with stock exchanges for the quarter ended March 31, 2026, in accordance with SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company submitted the mandatory documentation to both the National Stock Exchange and BSE Limited on April 10, 2026.

Regulatory Compliance Certificate

The certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 by the company's registrar and share transfer agent, MUFG Intime India Private Limited (formerly Link Intime India Private Limited). The compliance document covers the quarter ended March 31, 2026.

Share Transfer Agent Confirmation

MUFG Intime India Private Limited, serving as the registrar and share transfer agent, confirmed in their certificate that no demat requests were received for processing during the quarter ended March 31, 2026. The registrar stated that all shares of Sudeep Pharma Limited are held in electronic mode only, eliminating the need for any dematerialization processing.

The confirmation was signed by Damodar Kambli, Assistant Vice President at MUFG Intime India Private Limited, and bears reference number CSC/SUDEEP/2026. MUFG Intime India Private Limited operates from their registered address at C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai.

Company Secretary Filing

Company Secretary and Compliance Officer Dimple Mehta (Membership No. F13184) digitally signed and submitted the compliance certificate to both stock exchanges. The filing ensures the company meets its regulatory obligations under SEBI depositories regulations.

The pharmaceutical company, headquartered at 129/1/A, G.I.D.C. Estate, Nandesari, Vadodara, Gujarat, continues to maintain full compliance with SEBI regulations regarding depositories and participant requirements. The quarterly certificate submission represents standard regulatory practice for listed companies to confirm the status of their share dematerialization processes.